Heritage Pharmaceuticals Inc.

Generic SupplementsGeneric Supplement 2013

Heritage Pharmaceuticals Inc. is a rapidly expanding specialty pharmaceutical company focused on the acquisition, licensing, development, marketing, sale, and distribution of both generic and legacy branded pharmaceutical products for the US prescription drug market. Founded in 2006, Heritage currently markets 40 generic prescription products within a portfolio of 120 SKUs. The company’s core product line covers a number of therapeutic categories, including oncology, cardiovascular health, metabolic disease, anti-infective control, and pain management. Heritage is the exclusive US commercial footprint for Emcure Pharma Ltd. (India). As one of the Emcure group companies, Heritage works in close cooperation with Emcure’s global R&D and business development teams to optimize strategies for product pipeline selection and continued product acquisition across all product dosage forms. Most recently, Emcure-Heritage acquired the global rights to an exclusive oncology brand product, BiCNU® (Carmustine for injection), which serves as an anchor product in its growing oncology franchise. On target with its aggressive growth plan, Heritage anticipates 10 new launches before the end of 2013.

Heritage utilizes an integrated global supply network that leverages exclusive access to FDA-approved manufacturing and development facilities in both North America and Asia, including active pharmaceutical ingredients and finished dosage forms across oral solid, injectable, and cytotoxic capabilities. These sites have proven safety and compliance histories and provide dedicated access to raw materials and production capacity. The result is a supply chain that delivers flexibility, economies of scale, and rapid market distribution.

“Our focused business model leverages our considerable global resources to partner with major US national accounts, including chain pharmacies, wholesalers, distributors, hospitals, and managed care providers,” said Heritage President & CEO Jeffrey Glazer. “The result has been consistently growing net sales at a compound annual growth rate (CAGR) of 70% since 2009 while maintaining excellent distribution service levels, and we are on track to meet our goal of becoming one of the top 15 US generic companies by revenue within the next 5 years.”

Built on an established foundation of oral solid products, Heritage is positioned for pivotal expansion into the injectable and specialty pharmaceuticals businesses. “Our results and growth demonstrate the strength of our product line, operations team, and sales force,” said Glazer. “Our alliance with Emcure will allow us to continue to make significant inroads in the coming year in the injectable market segment—specifically in oncology.”

In an effort to promote cost-effective health care, the generic drug share comprises approximately 80% of all prescription orders filled in the United States. To meet the growing demand, Heritage is expanding the scope of its product line through a comprehensive development strategy that includes heavy investment in R&D in addition to robust business development across the pharmaceutical dosage value chain. The stability of Heritage’s management team ensures the continuity of the company’s vision: to achieve accelerated growth as a globally integrated manufacturer and developer of high-quality value-driven pharmaceutical products that meet the needs of health care providers and patients.

On July 2, 2013, Heritage Pharmaceuticals Inc. announced the immediate availability of Doxycycline Hyclate delayed-release tablets in 75-, 100-, and 150-mg strengths. This product is the AB-rated generic equivalent to the antibiotic drug Doryx® and adds to Heritage’s robust portfolio of high-barrier, extended-release, oral solid products. According to IMS data for the 12 months ended May 2013, the US market for Doxycycline Hyclate approximated $160 million.

Doryx is a registered trademark of Warner Chilcott.

For more information, visit www.heritagepharma.com.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.